|
The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: ---------- Idox PLC - Woking, Surrey-based software company focuses on government services - As outlined in October, Idox expects revenue in financial year to October to be slightly below prior management expectations, while profitability and net debt is anticipated to be in line with prior expectations. Expects revenue of around £90 million, up from £87.6 million the year prior. Of this, recurring and repeatable revenue is expected to be £60 million, up from £54.5 million. This is partially offset by a reduction in non-recurring revenue to £30 million from £33.1 million. Order intake climbs to £108 million from £102 million the year prior, with strong increases in the Assets division and Geospatial data solutions. Full year adjusted earnings before interest, tax, depreciation and amortisation is expected of £27.0 million up from £26.1 million with an adjusted Ebitda margin of 30%. Continues to generate good cash flow and ends the financial year with net debt of £13.0 million compared to £9.9 million the year before. ---------- Costain Group PLC - Maidenhead, England-based construction and engineering company - Wins a five-year framework contract from Electricite de France SA to continue providing project controls services at EDF’s eight nuclear power stations across the UK. The extension of the Project Controls Resources Framework, worth £75 million to Costain over five years, will take Costain and EDF’s partnership through to 2030. Costain has been working with EDF since 2017. ---------- Image Scan Holdings PLC - Leicestershire, England-based provider of X-ray screening systems - Says it recently secures a double-digit unit contract with an Indian partner for the ThreatScan-LS1 system. The contract was awarded following a ‘highly competitive’ tender process. Chief Executive of Image Scan subsidiary 3DX-RAY Vince Deery comments: ‘These new systems will be delivered within a very short timeline, and we look forward to showcasing our latest innovations at Milipol Paris next week-a leading international event for safety and homeland security.’ ---------- Time To Act PLC - Stockton-On-Tees, England-based company focused on engineering technology for energy transition supply chain - Expects Diffusion Alloys, its principal business, to be in profit for both the financial year to March 2026 and 2027. For the combined period, Time to Act forecast Ebitda of more than £1.0 million, and for the business to be profitable at the pre-tax level in each of the two years. While project activity has been slow, Diffusion Alloys is closing in on around £4 million to £5 million of large project work and it is ‘likely that the majority of these orders will be executed during the 2026 calendar year,’ company says. Revenue forecasts remain ‘under review’ given the difficulty in predicting the timing of order bookings or commencement of work. ‘That said, gross profit margins have been strong and are expected to remain so,’ Time to Act adds. In addition, company believes that the group has sufficient working capital for a period of at least 12 months. Time to Act also announces that Oberon Capital is appointed as joint broker with immediate effect. ---------- Aeorema Communications PLC - London-based live events agency - Expects revenue to be no less than £29.0 million in the 18 months to December compared to £27.5 million in the 18 months to December 2024. Sees underlying pretax profit, excluding one-off restructuring costs, of no less than £700,000 more than double £318,000 in the prior 18-month period and pretax profit of no less than £390,000, up from £318,000. ‘This improvement in profitability is supported by the operational benefits of restructuring, a growing pipeline of retained and new client work, and a sharpened focus on improving margins,’ company says. Aeorema says it remains committed to delivering shareholder returns and has adopted a progressive dividend policy linked to growth in earnings per share. ‘As we approach our new financial year, we are focused on converting our momentum into margin growth and shareholder value,’ Chief Executive Steve Quah says. ---------- Thor Explorations Ltd - Vancouver, Canada-based mining company targeting West Africa - Reports Ebitda of $51.8 million in the third quarter of 2025 up from $27.4 million the year prior, as revenue jumps to $69.9 million from $40.2 million. Sells 19,650 ounces of gold at an average gold price of $3,535 per ounce in the quarter at an all-in sustaining cost of $1,129 per ounce sold. For 2025, narrows production guidance to 90,000 ounces to 95,000 ounces from 85,000 to 95,000 before, and AISC guidance is narrowed to $900 to $1,000 per ounce from $800 to $1,000. ---------- CVS Group PLC - Norfolk, England-based provider of veterinary services - Sales rise 5.7% and adjusted Ebitda increases 6.2% in the four months to October 31 year-on-year, with like-for-like sales growth of 2.5% year-to-date. CVS notes Healthy Pet Club membership increases to 520,000 members as at the end of October from 507,000 the year prior mainly due to new clients transitioning from legacy schemes linked to historical UK practice acquisitions. Flags a ‘strong pipeline of future acquisition opportunities’ in Australia following recent deals. Looking ahead, CVS remains confident in delivering full year 2026 results in line with market expectations. While ‘mindful of continued headwinds in the UK particularly ahead of the UK government budget’, CVS says the ‘fundamental need for high-quality veterinary care remains strong, the growth opportunities in Australia are abundant and, following the conclusion of the CMA process, the group is confident of a return to acquisitions in the UK.’ ---------- Roquefort Therapeutics PLC - London-based biotechnology company, which focuses on developing medicines in the immunology and oncology sectors - Enters into a binding exclusive license agreement with Coiled Therapeutics Inc and A2A Pharmaceuticals Inc regarding the worldwide exclusive rights to AO-252, a clinical stage, novel first-in-class, first in-human new drug alternative targeting the transforming acidic coiled coil protein for the treatment of multiple cancers. Coiled Therapeutics, a clinical stage oncology company and a spin-out of A2A Pharmaceuticals, pays Roquefort £25.5 million upfront for worldwide exclusive rights to AO-252 plus further payments for development milestones and annual net sales royalties of up to 4%. In addition, Roquefort plans to move to AIM market from the Main Market of the London Stock Exchange and to raise £10.5 million via a placing at 1.7 pence per share. Upon completion of the transaction it is proposed that the name of the company be changed to Coiled Therapeutics PLC. As part of the placing, A2A Pharma and other investors introduced by A2A Pharma, are obliged to cornerstone with an investment of £3 million. Proceeds will be used to progress AO-252 through clinical trials, prepare the STAT-6 program for clinical trials and to provide additional working capital. On completion, senior executives from A2A Pharma and Coiled USA, including Sotirios Stergiopoulos and Sridhar Vempati will join the board as chair and chief executive respectively. ‘This transaction is transformative for Roquefort Therapeutics and realises our revised strategy to pivot towards targeting clinical stage assets,’ says Roquefort Chair Stephen West. ---------- CelLBxHealth PLC - Guildford, England-based liquid biopsy company, formerly called Angle PLC - Enters into a deal with Qiagen NV. The deal mean sample and assay technologies firm Qiagen can provide CelLBxHealth’s Parsortix platform to its pharmaceutical partners. ‘Partnering with a global provider of assay technologies for molecular diagnostics, is illustrative of the company’s key focus in driving commercial progress,’ the AIM listing says. Pact covers the joint promotion of the Parsortix platform and Qiagen’s molecular technologies to pharmaceutical and biotechnology partners, the establishment of laboratory services projects, a commitment to explore integration of Qiagen’s technologies and the opportunity for the development of a companion diagnostic assay or similar product incorporating both companies’ technologies. ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
